Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 4
1(20.0%)
5Total
Phase 2(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02445716Phase 2Unknown

Transdermal Testosterone Nanoemulsion in Women Libido

Role: lead

NCT02467673Phase 2Completed

Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy

Role: lead

NCT02582892Phase 4Completed

Systemic Vitamin D Supplementation in Dental Implants Patients

Role: lead

NCT02215434Phase 2Completed

Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women

Role: lead

NCT02033512Phase 2Completed

TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS

Role: lead

All 5 trials loaded